 Hi, how's everybody doing today? I am your host, Rich, here on behalf of RichTV Live with our very special guest, the CEO of Valeo Pharma, Steve Saviak. How are you doing today, Steve? Very good. Thanks for having me, Rich. Thank you for joining us. Very excited to have you on the show. Your company's been a huge success for our community already. Thank you for that. And we're really excited about learning more directly from the CEO. Why don't we get started right away, Steve, and you can tell us a little bit about Valeo Pharma and how long you've been with the company. Valeo was created in 2003. I co-founded the company with a couple other ex-pharma executives. So it's been around this year. We celebrated our 17th anniversary. It's had, you know, over the 17 years, we've had kind of what some people refer to as Valeo 1.0, Valeo 2.0. For the first period until about 2014, 2015, we in-licensed a number of drugs. We had a very successful business. But in 2014, we sold our products to Valeint, which is now Bosch Health. We had an extensive dermatology portfolio. They were very interested in that. So we sold those products as well as our hospital business. So we sold the products, not the company. We kept the name. We kept the same core management team. And basically launched what I like to refer to as Valeo 2.0, which is new therapeutic areas, so new areas of disease in terms of whether it be neurology diseases or oncology or, again, back in the hospital. So those are our three areas that we currently focus on. So it's been a very exciting time for us over the last 17 years. And I think the future bodes well also. I do too. I love what you guys are doing. And does Valeo Pharma have any main competitors? And if so, who are they? The pharmaceutical industry, as you know, in the world, or specifically in Canada, because we're a Canadian-focused company, there are many pharmaceutical providers. And that ranges all from the top of the Pfizer's and the Merck's and the GSK and what have you, the bigger companies, down to smaller companies such as us. I would put us in a, I would say we're on a small tier moving to mid tier based on the revenues that we're starting to see happen based on our growing number of employees. So we would be, in our peer group, as far as public companies are concerned that some of your viewers may be aware of, I would look at companies like HLS. I would look at companies like Knight, Therapeutics, Medexus, which is starting to do very well now. That would be another company we would be sort of peered to. So those are probably the three that I think most closely resemble, not only our business model, but certain other aspects of our operations. But what separates us from these companies is the number of factors. But one in particular is we don't all go after the same disease states or what we call same therapeutic areas. So some companies might want to focus on cardiology or on women's health. So our focus, again, is on neurology, oncology and the hospital. So there is a little bit of overlap with these companies, but there's also probably a lot of positive interaction that we have with them because in many case times we're not competing, we're actually exchanging information. Now you mentioned that you guys are going from small tier to mid tier. So how soon can we expect to see revenues impact value of Pharma's financial results? Well, our revenues for have been growing ever since the rebirth of the company following the sale to Valiant. Revenues for our last fiscal year were in excess of $8 million. Our fiscal year ends October 31st. So that's the year that just finished a couple of months and a bit ago. This year, our 21 year, we expect revenues in the 20 to 25 million range, over 100% increase. So we're starting to see the increase in revenues based on organic growth of our existing products and the addition of what we had four products launched in the last quarter of 20 of our fiscal 20 years. So that's they had a little bit of impact in 20. We'll see more impact in 21. And this year where we see the big growth is in two specific products, Redesca, which was we announced, we just received approval yesterday from Health Canada. And the other product is Hisperco, which is our immune support product. It's our first over the counter product, which has been launched about a month ago and will be in major retailers across Canada within the next month or so. That's great. Now, you just recently, and you mentioned this, had some big news, which we talked about yesterday from Health Canada on the approval of Redesca. Congratulations. Thank you. And how big is the heparin market and how much of it can Redesca target? So the so Redesca is is what's known as a biosimilar. It's a very it's a means is biologically similar to a biologic drug. The low molecular weight heparin market in Canada is about 200 million dollars. Now, when we talk about low molecular weight heparins, what do they do? They're essentially anticoagulants in more simplistic terms. They're blood thinners. They prevent blood clots from forming. They're used predominantly in the hospital. They're used after many certain types of surgeries. And you can imagine things such as a knee implant, hip implant, cardiac surgery. Anytime you're you've had surgery, your blood written in the hot and your bed written in the hospital. What physicians are concerned about is the creation of blood clots in your extremities, your arms, your legs. And if these blood clots migrate to your lungs, you have very serious consequences and potentially fatal consequences. So the way this is regulated is through the use of heparin. So it's very it's used every day. And that's why the market in all hospitals across Canada, I don't think there's a hospital in Canada does not have low molecular weight heparin of some type in its in its pharmacy. And as I mentioned, the market is about $200 million. What percentage of that market we expect to attain is about 15 to 20%. We think we have an excellent product. We have an excellent source of supply. And that's not to be overlooked in the heparin market, where there are shortages from time to time. We have a very convincing clinical package, which differentiates us. And we have a complete lineup of the products from, I think there's eight different stock keeping units. So eight different formats that are being offered, which is the full range that's typically available in Canada. So those factors give us a strong sense that we will be able to achieve that market share. And what without getting into too much detail about biosimilars and what have you, biosimilars in Canada are being introduced and essentially in various against various drugs, remiccate is a biologic that biosimilars have been used, have been launched against. And what biosimilars have done in Canada has driven down the costs of healthcare. This is one of the big advantages of a biosimilars, the savings that they provide the healthcare system. And the provinces are actually looking at and started in BC and is moving east, actually mandating the use of biosimilars. That also is a benefit to us. So we're coming in with a great product, great clinical package, lower price than the, let's say the competition still provides very attractive margins to us. So it's a win-win for the patient for us and for the Canadian healthcare system. Now you mentioned this a little bit. What are the peak sales for the product? I think you said out of a 200 million market 15 to 20%. That's 30 to 40 million dollars. That's pretty substantial. And how quickly can we see it get there? You know, when people ask that question often, because we have currently we're marketing eight products and we have seven more in a pipeline of which Redesca is one of them. They say how quickly do you get to peak sales? Peak sales is how many pharma companies like to look at their products. How big can this product get in the Canadian market or whatever market they're talking about? And that varies depending on the type of product. But specifically for a product like Redesca, you're looking at peak sales within 1824 months from launch on strive, which is our Parkinson's drug, which was launched in July 2019. Peak sales will come through it probably in year four or year five. So there's a lot of known factors that affect when peak sales typically can be achieved. But fortunately for us, Redesca is on the shorter end of that. So we should start seeing sales hitting our financial statements in the first half of 2021. Wow, that's impressive. That's exciting, guys. So for early investors that want to get in early, that is going to be a huge jump in revenue for the company. How does Redesca differentiate itself from the competition? Well, again, the differentiation in terms of its effectiveness is not how you have to look at Redesca. How it differentiates itself from the competition is its breadth of product. So the various formats it comes in. It's clinical package. So it has a very, it's been tested over, it's been in the market in other countries for over eight years. In Europe alone, over 150 man days of use of Redesca. So for instance, so for every day a patient is taking Redesca is considered one mandate in Europe, 150 man days, very, very below or very safe, a very good safety profile, low incidence of adverse events. So these are some of the advantages that will be marketed to the hospitals across Canada. So very safe product, very good quality. And clearly the big advantage to is price savings for hospitals and that price saving will range anywhere from 10 to maybe 20, 25%. So, you know, big when you're looking at a $200 million market for hospitals, these are big savings. Absolutely. And what can we expect from the company short and midterm? In terms of our short term drivers, what people will hear about from value is certainly the growing revenue will start to maybe hear about some other products that we're currently working on in licensing into the into the company. But in the short term, it's really the news will be around Redesca and its ultimate launch and some of the early successes we have in the entertaining market share. The other product that's gaining a lot of attention now is a product we launched about a month ago, which is called Hisperco. And Hisperco is our first product, which is an over the counter product. So it's available in pharmacies without a prescription. It's used for immune support. So when you look at immune support, you're looking at, well, what does that necessarily mean? It helps your immune system combat viral infections. So your viral infections is the flu, the common flu is a viral virus that infects your body. So you can imagine with this current pandemic situation that our immune systems are being attacked and need the maximum amount of support. There's a lot of scientific data that supports that this product or the Hisperidine, which is the active ingredient in Hisperco has shown effectiveness at controlling symptoms of a number of different viruses, including the coronavirus. Now, when I say coronavirus, I'm not talking necessarily COVID-19, although there will be some clinical activity we'll be performing to try to show that. But a number of the common flus that we get in the in the fall time or spring time are coronaviruses. I mean, this is a virus family that's been around for quite some time. So there's been specific science that shows that it reduces the symptoms of these viral infections. So I think this is very important for people to take. It's a very low cost, about a dollar a day. We're currently available on Amazon.ca soon to be available in all major pharmacy retailers across Canada when I say soon, probably the beginning of next year, so two three weeks. And our intention is to go into the US with this product. So again, good margin product, very effect very effective on the cost per day. We think that all, you know, all patients should all Canadians should be on this. In fact, everyone who works for Valeo takes Hisperco and we don't get it for free. We have to buy it from the company. So it's it's we feel very strongly about it. And anyone who wants to to know more about it can certainly contact me or visit a website from our partner. Our partner is called Ingenu Pharma. When I say a partner, it's a small biotech company in Montreal that developed a concept around Asperidine that dug out some of this scientific data that supports the activity of of Asperidine. Go to their website and you can read as much as you want to read, but it's it's really compelling. And I strongly encourage anyone that, you know, may feel run down or is maybe concerned about catching some type of viral infection to to take Hisperco. We've got investors from over 90 countries that are going to be watching this video, learning about Valeo Pharma. If there's one thing you want to take away, you want them to take away from this interview, what would it be? I would say that our, you know, the two things are growing portfolio, growing revenues. We're a fast growing company. And I think that, you know, for growth investors, you're always looking at that top line growth. And that's what we're demonstrating. We demonstrated the fourth quarter, and we'll be demonstrating it in fiscal 2021. So I think that it is one thing is that growth and that anticipated continued growth over really the next three, four years as we plan out, bodes well for for the company for Canadian health care system and for our shareholders. What is the best way for shareholders or potential investors to get in contact with the company if they want to get in touch with the company? Well, I would say to get ahold of me and probably the easiest way is not by phone, because it's just a two. It's just so difficult. But I would say to email me and I'll if I can answer your questions, I can we have a director of communications, Fred Dumé, who deals with investors and various institutions and analysts and what have you on a daily basis, but certainly send me an email. It's my last name, Saviak at valuefarmac.com and I'll be happy to answer personally, or I'll get someone else to contact you. That's great. Well, thank you so much for your time today. Steve Saviak, the CEO of value pharma. Now remember guys, Rich TV Live is strictly for education and entertainment purposes. Always do your due diligence. Always do your research before you invest in anything we talk about in Rich TV Live. Speak to a financial advisor. If you do, they're probably going to recommend value pharma. I recommend it. I think it's undervalued, underappreciated, under exposed. It's already been a winner for our community. If you guys are watching this video for the first time, smash the like button, comment down below, subscribe and share the video everywhere. I think value pharma has been a big winner for our community. And I believe this is a story that's just getting started. Steve, thank you for joining us on our show. Love to have you on again. And anytime you guys have any big breaking news, we will be watching and following very closely. Rich, thanks for having me. And we'll keep you up to date with all our news. Fantastic. Thank you so much, Steve. Thank you guys for watching. If you're not winning, you're not watching. We're bringing the winners and we bring them to you first. Steve Saviak, CEO of value pharma. Have a great day, Steve. Keep up the great work. Thank you guys for watching. We'll talk to you soon.